• Expanded product suite with Flamingo architecture; first contract secured in December 2025
• Recurring revenue of A$11.6M, 85% of total revenue; 78% coverage of OPEX
• Total revenue of A$13.7M, down 23% on pcp largely due to fewer one-off capital licence deals

Mach7 Technologies Limited (ASX:M7T), a healthcare software company, has reported its half year results for the six months ended 31 December 2025. The company's first half FY26 revenue was A$13.7M, 23% lower than the prior corresponding period, largely due to lower one-off capital software licence revenue, a reduction in recurring revenue following customer churn, and lower professional services revenue. However, recurring revenue accounted for 85% of total revenue and coverage of operating expenditure was 78% in H1 FY26. Operating expenses of A$14.8M were 6% lower on the prior corresponding period, mainly due to lower employment expenses and the realisation of operating efficiencies across the business. Adjusted EBITDA of -A$2.3M (H1 FY25: A$0.8M) was lower on the prior corresponding period as the lack of one-off capital software sales more than offset the reduction in operating costs. NPATA of -A$2.7M (H1 FY25: A$1.4) and NPAT of -A$5.7M (H1 FY25: -A$1.9M) were also lower on the prior corresponding period largely due to the revenue decline in H1 FY26. Mach7's financial position remains strong with no debt and A$18.5M cash on hand at 31 December 2025.

Mach7 continues to be a leading innovator in the enterprise imaging space, with a portfolio of interoperable solutions. As provider consolidation reshapes the healthcare landscape, Mach7 is well positioned to capitalise on these shifts, supported by a strong installed base and the continued global adoption of enterprise imaging. The company remains focused on disciplined cost management while selectively investing in growth-critical capabilities across sales execution, product development and platform scalability, including a significantly expanded marketing program to modernise its brand and market engagement. Underpinned by a re-energised sales and partner model and early traction for its Flamingo solutions, Mach7 remains confident in its ability to deliver against its strategy and capture emerging market opportunities.